Interferon regulatory factor 8 (IRF8) also known as interferon consensus sequence-binding protein (ICSBP), is a
protein that in humans is encoded by the IRF8gene.[5][6][7] IRF8 is a
transcription factor that plays critical roles in the regulation of lineage commitment and in
myeloidcell maturation including the decision for a common myeloid progenitor (CMP) to
differentiate into a
monocyte precursor cell.
IFN-producing cells (mIPCs) were absent in all lymphoid organs from ICSBP
knockout (KO) mice, as revealed by lack of CD11clowB220+Ly6C+CD11b− cells. In parallel, CD11c+ cells isolated from ICSBP KO spleens were unable to produce type I IFNs in response to viral stimulation. ICSBP KO mice also displayed a marked reduction of the DC subset expressing the CD8alpha marker (CD8alpha+ DCs) in spleen, lymph nodes, and thymus. Moreover, ICSBP-deficient CD8alpha+ DCs exhibited a markedly impaired phenotype when compared with WT DCs. They expressed very low levels of costimulatory molecules (intercellular adhesion molecule
ICAM1,
CD40,
CD80,
CD86) and of the T cell area-homing chemokine receptor
CCR7.[8]
IRF8 is highly expressed in myeloid cells and was originally identified in as a critical lineage-specific transcription factor for myeloid cell differentiation,[11] recent studies, however, have shown that IRF8 is also constitutively expressed in non-
hematopoietic cancer cells, albeit at a lower level. Furthermore, IRF8 can also be up-regulated by IFN-γ in non-hemotopoietic cells. IRF8 mediates the expression of Fas, Bax,
FLIP,
Jak1 and
STAT1 to mediate apoptosis in non-hemotopoietic cancer cells.[12][13][14]
Analysis of human cancer genomics database revealed that IRF8 is not significantly focally amplified across the entire dataset of 3131 tumors, but is significantly focally deleted across the entire dataset of 3131 tumors, suggesting that IRF8 is potentially a
tumor suppressor in humans.[15] Molecular analysis indicated that the IRF8 gene promoter is hypermethylated in human
colon carcinoma cells,[14][16] suggesting that these cells might use DNA methylation to silence IRF8 expression to advance the disease.
^
abYang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T, Ozato K, Ganapathy V, Abrams SI, Liu K (April 2007). "Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells". Cancer Res. 67 (7): 3301–9.
doi:
10.1158/0008-5472.CAN-06-4068.
PMID17409439.
Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS, Shinjo F, Liu Y, Dembowy J, Taylor IW, Luga V, Przulj N, Robinson M, Suzuki H, Hayashizaki Y, Jurisica I, Wrana JL (2005). "High-throughput mapping of a dynamic signaling network in mammalian cells". Science. 307 (5715): 1621–5.
Bibcode:
2005Sci...307.1621B.
doi:
10.1126/science.1105776.
PMID15761153.
S2CID39457788.
Dimberg A, Kårehed K, Nilsson K, Oberg F (2006). "Inhibition of monocytic differentiation by phosphorylation-deficient Stat1 is associated with impaired expression of Stat2, ICSBP/IRF8 and C/EBPepsilon". Scand. J. Immunol. 64 (3): 271–9.
doi:
10.1111/j.1365-3083.2006.01827.x.
PMID16918696.
S2CID22527134.
Interferon regulatory factor 8 (IRF8) also known as interferon consensus sequence-binding protein (ICSBP), is a
protein that in humans is encoded by the IRF8gene.[5][6][7] IRF8 is a
transcription factor that plays critical roles in the regulation of lineage commitment and in
myeloidcell maturation including the decision for a common myeloid progenitor (CMP) to
differentiate into a
monocyte precursor cell.
IFN-producing cells (mIPCs) were absent in all lymphoid organs from ICSBP
knockout (KO) mice, as revealed by lack of CD11clowB220+Ly6C+CD11b− cells. In parallel, CD11c+ cells isolated from ICSBP KO spleens were unable to produce type I IFNs in response to viral stimulation. ICSBP KO mice also displayed a marked reduction of the DC subset expressing the CD8alpha marker (CD8alpha+ DCs) in spleen, lymph nodes, and thymus. Moreover, ICSBP-deficient CD8alpha+ DCs exhibited a markedly impaired phenotype when compared with WT DCs. They expressed very low levels of costimulatory molecules (intercellular adhesion molecule
ICAM1,
CD40,
CD80,
CD86) and of the T cell area-homing chemokine receptor
CCR7.[8]
IRF8 is highly expressed in myeloid cells and was originally identified in as a critical lineage-specific transcription factor for myeloid cell differentiation,[11] recent studies, however, have shown that IRF8 is also constitutively expressed in non-
hematopoietic cancer cells, albeit at a lower level. Furthermore, IRF8 can also be up-regulated by IFN-γ in non-hemotopoietic cells. IRF8 mediates the expression of Fas, Bax,
FLIP,
Jak1 and
STAT1 to mediate apoptosis in non-hemotopoietic cancer cells.[12][13][14]
Analysis of human cancer genomics database revealed that IRF8 is not significantly focally amplified across the entire dataset of 3131 tumors, but is significantly focally deleted across the entire dataset of 3131 tumors, suggesting that IRF8 is potentially a
tumor suppressor in humans.[15] Molecular analysis indicated that the IRF8 gene promoter is hypermethylated in human
colon carcinoma cells,[14][16] suggesting that these cells might use DNA methylation to silence IRF8 expression to advance the disease.
^
abYang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T, Ozato K, Ganapathy V, Abrams SI, Liu K (April 2007). "Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells". Cancer Res. 67 (7): 3301–9.
doi:
10.1158/0008-5472.CAN-06-4068.
PMID17409439.
Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS, Shinjo F, Liu Y, Dembowy J, Taylor IW, Luga V, Przulj N, Robinson M, Suzuki H, Hayashizaki Y, Jurisica I, Wrana JL (2005). "High-throughput mapping of a dynamic signaling network in mammalian cells". Science. 307 (5715): 1621–5.
Bibcode:
2005Sci...307.1621B.
doi:
10.1126/science.1105776.
PMID15761153.
S2CID39457788.
Dimberg A, Kårehed K, Nilsson K, Oberg F (2006). "Inhibition of monocytic differentiation by phosphorylation-deficient Stat1 is associated with impaired expression of Stat2, ICSBP/IRF8 and C/EBPepsilon". Scand. J. Immunol. 64 (3): 271–9.
doi:
10.1111/j.1365-3083.2006.01827.x.
PMID16918696.
S2CID22527134.